What is the relative blood test for

EDIM blood test TKTL1 and Apo10

Last Updated on October 1, 2018 by Jacek

 

With the EDIM test EDIM-TKTL1 and EDIM-Apo10 blood test Early oral cavity cancer, breast cancer and prostate cancer are to be identified and recurrences to be detected.
This blood test is not specific for certain types of cancer, but can be used for all forms of carcinoma and sarcoma.

The test is also suitable for monitoring therapy.

Apo10 and TKTL1 stand for the aggressiveness of the tumor cells

With the EDIM-TKTL1 and EDIM-Apo10 blood tests, early detection of cancer in the blood and early detection of relapses should be possible.
The newly discovered tumor markers are new hope for cancer diagnostics.

TKTL1 and Apo10 are two protein compounds that are made in tumors to allow tumors to grow and spread.

While Apo10 indicates a lack of elimination, i.e. a non-death (apoptosis) of tumor cells, TKTL1 signals an increased sugar metabolism of tumor cells, which leads to metastasis as well as resistance to radiation therapy and chemotherapy.

 

EDIM method, Edim technology

Edim-Technology is an abbreviation for epitope detection in monocytes.

Only a small blood sample is required for the laser-based test. The Edim-Method is able to detect phagocytes that are circulating in the blood and which tumor cells take up, and to identify the tumor cell material in these phagocytes.

The immunological-diagnostic procedure EDIM was developed by the company Tavarlin AG.

Information on current studies was published in the scientific journal BMC Cancer.
The director of studies explained the processes PD Dr. Dr. Martin Grimm from the Molecular Biology Laboratory of the Clinic and Polyclinic for Oral and Maxillofacial Surgery at the University Hospital.

  • In the first part of the study, the archived material from 161 Tübingen patients with malignant neoplasms of the oral mucosa was examined.
  • In the second part of the study, 50 patients with primary or relapsed carcinoma of the oral mucosa, 48 with breast cancer and 115 with post-cancer cancer were prospectively tested for Apo10 and TKTL1 before their operation.
  • Samples from 74 healthy blood donors served as controls.

In the tests with the EDIM method, both markers were detected in almost all cancer patients.
Apo10 was found in the sections of 82% of the tumors, TKTL1 in 42%.

With the help of a combination of the scores it was possible to detect the carcinoma in all three examined different forms of carcinomas with the same threshold value (score) of 227

  • 96% of patients with cancer of the oral mucosa,
  • 98% with breast cancer and
  • 97% with prostate cancer.

 

EDIM-TKTL1 and EDIM-Apo10 blood test Use in daily practice

Before such a blood test for tumor markers can be used in daily practice, however, further studies are necessary.

Whether such studies are initiated will also depend on the results of further analyzes of the study that has just been completed.

In addition, it still needs to be clarified what exactly the test could be used for. It is currently not recommended for screening (supposedly) healthy people, as the data are not yet sufficient for this. Small micro-invasive carcinomas could, however, be discovered in the current study using EDIM.

EDIM test costs

The EDIM test is carried out by determining Apo10 and TKTL1 in immune cells, so these work steps can already be billed by laboratory doctors as immunophenotyping for tumor diseases.

So far, the test has been offered exclusively by the Biovis laboratory in Limburg. In patients with proven tumor disease, the blood test will be reimbursed by private health insurances and, under certain circumstances, also by statutory health insurances.
The test is available from € 148 for self-payers.

Contact person for EDIM test for therapists:

If you are interested and have questions about the EDIM test, please contact:

biovis' Diagnostics MVZ GmbH
Tel .: +49 (0) 64 31 - 21248 - 0
[email protected]
/www.biovis-diagnostik.eu